SlateXpace

• A new breed of multimodal manufacturing
• A @CRBgrp solution

[SlateXpace @SlateXpace]

Time to market is critical, especially when it comes to cancer treatment. Learn how a SlateXpace programming study concluded that our client could save up to 50% on overall project schedule compared to a traditional design-bid-build project delivery: https://t.co/0otRy0xxRI

[SlateXpace @SlateXpace]

SlateXpace, a @CRBgrp solution, is a new breed of manufacturing facility. One that is designed to campaign smoothly between modalities – offering flexibility, scalability & ease to validate & operate. Learn more: https://t.co/ex5uZImdZ0 #multimodal

[SlateXpace @SlateXpace]

#Multimodal is the future. Of the nearly 500 life science industry leaders surveyed for this year's Horizons: #LifeSciences report, 91% said they are or plan to develop & manufacture multiple therapy modalities in a single building. Download the report: https://t.co/kjr5WNoVGs

[SlateXpace @SlateXpace]

A turbulent supply chain has made #ATMP manufacturers anxious about the quality, reliability & cost of raw materials. This is where a #modular, multi-modal #GMP facility comes in with deeper vertical integration. Learn more about the benefits: https://t.co/pp0uATaKTe

[SlateXpace @SlateXpace]

We asked & nearly 500 #lifesciences industry leaders answered. In this 3rd edition of Horizons: Life Sciences, deep dive w/ our experts to understand data-driven trends & challenges #biopharma companies face & what the future holds. Download for FREE: https://t.co/BAqCmJnpmQ

[SlateXpace @SlateXpace]

Time has flown by! 2 years ago, we started this journey to revolutionize the #pharmaceutical manufacturing facility. We developed a #multimodal solution that is flexible, scalable & easy to validate & operate. We created SlateXpace! Let's celebrate! https://t.co/9Xnmo4YMhP

[SlateXpace @SlateXpace]

Don’t miss this opportunity to sign up early for Horizons: Life Sciences. This must-have report takes you deep into data from nearly 500 industry leaders – from the challenges they face to the future they envision. Sign up today: https://t.co/vaftT7TQk3

[SlateXpace @SlateXpace]

Today’s #pharma manufacturers face immense pressure to move fast, develop complex product pipelines & scale up quickly & cost-effectively. SlateXpace is a new breed of manufacturing facility designed to transition smoothly between modalities: https://t.co/mBoqyAHgaD

[SlateXpace @SlateXpace]

SlateXpace is there to help you compete in a world that is always changing. It’s more than flexible manufacturing, it’s a solution that rethinks how we design and build facilities so they can evolve alongside your product pipeline. Learn more: https://t.co/Z9UDTHSBgf

[SlateXpace @SlateXpace]

Today’s #ATMP manufacturers need agile, reconfigurable #GMP environments that can support multi-product pipelines. SlateXpace is a #multimodal facility with built-in flexibility, less risk and a higher probability of return. Learn more: https://t.co/uO3kD8BiCm

[SlateXpace @SlateXpace]

Many life sciences companies describe their newest innovations as “disruptive.” But how many innovations are truly changing the industry for the better? Noel Maestre offers his thoughts on finding the true meaning of disruption in @medicine_maker >> https://t.co/bZ3KTQCDvu

[SlateXpace @SlateXpace]

Europe’s R&D sectors are driving the need for the #lifesciences industry to expand and modernize its #manufacturing infrastructure. Rasmus Kidmose explains why these companies should leverage a hybrid partner w/ global expertise & local knowledge: https://t.co/icMA1ygODx

[SlateXpace @SlateXpace]

Designing an #ATMP facility under uncertain conditions can be challenging & risky. At @ACHEMAworldwide on 8/24, Niranjan Kulkarni will outline using process models & discrete event simulations for designing & right-sizing ATMP facilities. Learn more: https://t.co/BsYzRv7SI9

[SlateXpace @SlateXpace]

As the #pharmaceutical industry undergoes seismic shifts, manufacturers need to move faster to manage multiple, complex product pipelines. In a whitepaper w/ @Biophorum, JP Bornholdt & Charles Heffernan explain how modular design has significant benefits: https://t.co/pTZrFe3pF1

[SlateXpace @SlateXpace]

Point-of-use manufacturing has the potential to help make medicines more accessible globally. This is especially important after the COVID-19 pandemic showed the shortcomings of traditional manufacturing. Peter Walters spoke w/ @PharmTechGroup: https://t.co/5W5UaDfK0O

[The Medicine Maker @medicine_maker]

Disruptive technologies are often talked about in pharma circles. But when it comes to AI, what long-term impact will it have? Noel Maestre, Vice President of Life Sciences at @CRBgrp shares his views.
https://t.co/5YmbcRD16l

[SlateXpace @SlateXpace]

Our president, Ryan Schroeder, says it best - SlateXpace is a #multimodal solution that is highly agile, scalable and efficient that allows our #lifesciences clients to campaign between modality-specific process platforms. Learn more: https://t.co/UgOF8pBvWP

[SlateXpace @SlateXpace]

Wishing you a happy and safe #IndependenceDay!

#CRBLife

[SlateXpace @SlateXpace]

As the #pharmaceutical industry continues to undergo a seismic shift, the need for speed and agility is greater than ever. That's where SlateXpace™ comes in w/ our modular solution offering unparalleled speed-to-market, cost efficiency and adaptability: https://t.co/yoHh74gvrX

[SlateXpace @SlateXpace]

SlateXpace is celebrating #PrideMonth w/ our Out+Allies employee resource group. This group of #LGBTQ+ employees and allies are committed to fostering a welcoming & #inclusive workplace, providing visibility to the LGBTQ+ community, & promoting individual diversity & uniqueness.